ArticleNPJ precision oncology2025
Collagen disorder architecture features are associated with clinical, molecular, genetic factors and survival outcomes in colon cancer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DDR2-COL11A1 Transcriptional Coupling as a Candidate Therapeutic Target in Colorectal Cancer: Integrative Transcriptomic and Deep Learning Validation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
We developed a computational pathology pipeline to extract and analyze collagen disorder architecture (CoDA) features from whole slide images (WSIs) of 2,212 colon cancer (CC) patients across multiple institutions. CoDA features-capturing collagen fragmentation, bundling, anisotropy, density, and rigidity, were evaluated for associations with clinical variables (overall stage, T/N/M stage), molecular classifications (Consensus Molecular Subtypes [CMS1-4]), and genetic mutations (KRAS, BRAF, NRAS) using the Mann-Whitney U test with Bonferroni correction. These analyses revealed significant differences in CoDA feature distributions across multiple subgroups, suggesting that collagen architecture varies meaningfully with tumor stage, molecular subtype, and mutation status.To assess how well CoDA features could distinguish between these subgroups, we implemented a Random Forest classification framework. High mean AUC values (≥0.7) across several variables indicated strong discriminatory performance of CoDA features in separating clinically and biologically distinct groups.For survival analysis, LASSO-Cox models were trained on the PLCO dataset to generate CoDA-based risk scores for overall survival (OS) and disease-free survival (DFS), which were used to stratify patients into high- and low-risk groups in a combined validation dataset (TCGA, UH, and Emory). Kaplan-Meier curves demonstrated significant survival differences across clinical stages, CMS subtypes, and KRAS mutation status. Multivariable Cox proportional hazards models further confirmed the independent prognostic value of CoDA features after adjusting for clinical, molecular, and genetic covariates. These findings highlight that CoDA features are significantly associated with key clinical and molecular characteristics, can distinguish relevant patient subgroups, and offer independent prognostic information, underscoring their potential utility in characterizing the tumor microenvironment and informing risk stratification in CC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.